Skip to main content
. Author manuscript; available in PMC: 2022 May 10.
Published in final edited form as: Cytometry A. 2022 Apr 1;101(6):483–496. doi: 10.1002/cyto.a.24552

Figure 4. Assessing the ability of antibodies to SARS-CoV-2-infected cells to mediate NK cell degranulation.

Figure 4.

A gating strategy identifying singlets, lymphocytes and live cells was used to detect cells followed by excluding non-NK cell events and gating for CD107a+ NK cells on mock infected and SARS-CoV-2-infected cells (A). No plasma, plasma from an uninfected individual and plasma from an infected individual were used to assess specificity of NK cell degranulation in the presence or absence of plasma and mock infected or SARS-CoV-2-infected cells (B). The %CD107a+ NK cells detected using plasma from a single infected individual which was diluted to three different dilutions (1:100, red; 1:500, orange and 1:1000, yellow) (C). The AUC of %CD107a+ NK cells cells at three dilutions (1:100, 1:500 and 1:1000) was calculated for uninfected controls (n=20) and SARS-CoV-2-infected individuals (n=50) (D).